Published on: Jan 03, 2018 at OncLive

FDA Approvals in RCC and CML, Priority Review Designations in NSCLC and RCC, and More

By : OncLive

The European Union’s Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Herzuma, a trastuzumab biosimilar, for treating HER2-positive gastric cancer patients. The CHMP’s opinion now goes to the full European Commission for final review.

Read More
SHARE